ArticleACS omega2018
Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer.
Open access · goldAbstract read
In one paragraph
Article in ACS omega, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Structures of dynamic interactors at native proteasomes by PhIX-MS and cryo-electron microscopy.Molecular cell · 2026Article
- Fatty acid uptake mediated by FABP4 promotes the formation of CD8Oncogenesis · 2026Article
- Exploiting Avidity Effects for the Discovery of Low Affinity Protein-Binding Fragments.Journal of medicinal chemistry · 2025Article
- NMR-Guided Studies to Establish the Binding Interaction between a Peptoid and Protein.Journal of the American Chemical Society · 2025Article
- A structure-based designed small molecule depletes hRpn13Nature communications · 2024Article
- hRpn13 shapes the proteome and transcriptome through epigenetic factors HDAC8, PADI4, and transcription factor NF-κB p50.Molecular cell · 2024Article
- Preclinical studies of RA475, a guanidine-substituted spirocyclic candidate RPN13/ADRM1 inhibitor for treatment of ovarian cancer.PloS one · 2024Article
- Targeting endoplasmic reticulum stress signaling in ovarian cancer therapy.Cancer biology & medicine · 2023Review
- Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor.PloS one · 2023Article
- Proteasome substrate receptors and their therapeutic potential.Trends in biochemical sciences · 2022Review
- Structure-guided bifunctional molecules hit a DEUBAD-lacking hRpn13 species upregulated in multiple myeloma.Nature communications · 2021Article
- Proteasome interaction with ubiquitinated substrates: from mechanisms to therapies.The FEBS journal · 2021Review
- Article
- Structure, Dynamics and Function of the 26S Proteasome.Sub-cellular biochemistry · 2021Review
- Impact of Losing hRpn13 Pru or UCHL5 on Proteasome Clearance of Ubiquitinated Proteins and RA190 Cytotoxicity.Molecular and cellular biology · 2020Article
- Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling.BMC cancer · 2020Article
- An Extended Conformation for K48 Ubiquitin Chains Revealed by the hRpn2:Rpn13:K48-Diubiquitin Structure.Structure (London, England : 1993) · 2020Article
- Structure of E3 ligase E6AP with a proteasome-binding site provided by substrate receptor hRpn10.Nature communications · 2020Article
- Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease.Molecules (Basel, Switzerland) · 2020Review
- Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Ravi K AnchooriDepartment of Oncology, Department of Pathology, and Department of Gynecology and Obstetrics, The Johns Hopkins University, Baltimore, Maryland 21231, United States.
Rosie JiangDepartment of Oncology, Department of Pathology, and Department of Gynecology and Obstetrics, The Johns Hopkins University, Baltimore, Maryland 21231, United States.
Shiwen PengDepartment of Oncology, Department of Pathology, and Department of Gynecology and Obstetrics, The Johns Hopkins University, Baltimore, Maryland 21231, United States.
Ruey-Shyang SoongDepartment of Oncology, Department of Pathology, and Department of Gynecology and Obstetrics, The Johns Hopkins University, Baltimore, Maryland 21231, United States.
Aliyah AlgethamiDepartment of Oncology, Department of Pathology, and Department of Gynecology and Obstetrics, The Johns Hopkins University, Baltimore, Maryland 21231, United States.
Michelle A RudekDepartment of Oncology, Department of Pathology, and Department of Gynecology and Obstetrics, The Johns Hopkins University, Baltimore, Maryland 21231, United States.
Nicole AndersDepartment of Oncology, Department of Pathology, and Department of Gynecology and Obstetrics, The Johns Hopkins University, Baltimore, Maryland 21231, United States.
Chien-Fu HungDepartment of Oncology, Department of Pathology, and Department of Gynecology and Obstetrics, The Johns Hopkins University, Baltimore, Maryland 21231, United States.
Xiang ChenProtein Processing Section, Biophysics Resource, and Basic Science Program, Leidos Biomedical Research, Inc., Biophysics Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
Xiuxiu LuProtein Processing Section, Biophysics Resource, and Basic Science Program, Leidos Biomedical Research, Inc., Biophysics Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
Olumide KayodeProtein Processing Section, Biophysics Resource, and Basic Science Program, Leidos Biomedical Research, Inc., Biophysics Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
Marzena DybaProtein Processing Section, Biophysics Resource, and Basic Science Program, Leidos Biomedical Research, Inc., Biophysics Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
Kylie J WaltersProtein Processing Section, Biophysics Resource, and Basic Science Program, Leidos Biomedical Research, Inc., Biophysics Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
Richard B S RodenDepartment of Oncology, Department of Pathology, and Department of Gynecology and Obstetrics, The Johns Hopkins University, Baltimore, Maryland 21231, United States.
Johns Hopkins University · USLeidos (United States) · US
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6MInstitute for Clinical and Translational Research (UL1)UL1RR025005 · NCRR · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2007 to 2011
$75.8MTreatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI Richard Bruce Roden · 2003 to 2026
$53.5MUbiquitin signaling for protein degradationZIABC011490 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WALTERS, KYLIE · 2013 to 2025
$21.1MCCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS P30 CA006973NCI NIH HHS P50 CA098252NCRR NIH HHS UL1 RR025005
Abstract
Substitution of the
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.